European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies

Heidrun Boztug, Karl Walter Sykora, Mary Slatter, Marco Zecca, Paul Veys, Arjan Lankester, Andrew Cant, Roderick Skinner, Jacek Wachowiak, Evgenia Glogova, Ulrike Pötschger, Christina Peters

Research output: Contribution to journalArticle

Abstract

Background: Standard myeloablative conditioning regimens for children with hematological malignancies undergoing allogeneic HSCT are based mainly on total body irradiation or busulfan. Their serious short-and long-term side effects warranted the exploration of less toxic alternatives. Treosulfan is increasingly used for adults and children before HSCT due to its potent immunosuppressive and cytotoxic effects combined with low organ toxicity. Procedure: To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010. Results: Early regimen-related toxicity was low and mainly gastrointestinal. Veno-occlusive disease and neurological toxicity were rare. There was no association of toxicity with type of disease or treosulfan dose. High-grade early toxicity was not higher in infants or patients undergoing second or later transplantation. Treatment related mortality was low at 14%. Three-year event-free survival was 45±4% and not significantly influenced by number of transplants, however it appeared to be significantly better for infants (P = 0.022). When compared to treosulfan plus fludarabine, the combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) resulted in significantly better overall survival (OS, P = 0.048) and a trend toward better EFS. Conclusions: Treosulfan based conditioning is a safe and effective approach for children with hematological malignancies, including and importantly for infants and those patients undergoing second or later transplantation.

Original languageEnglish
Pages (from-to)139-148
Number of pages10
JournalPediatric Blood and Cancer
Volume63
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

treosulfan
Hematopoietic Stem Cell Transplantation
Hematologic Neoplasms
Transplantation
Bone Marrow
Thiotepa
Busulfan
Melphalan
Whole-Body Irradiation
Poisons
Alkylating Agents
Immunosuppressive Agents
Disease-Free Survival
Lymphoma

Keywords

  • Children
  • Hematological malignancy
  • Stem cell transplantation
  • Toxicity
  • Treosulfan

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. / Boztug, Heidrun; Sykora, Karl Walter; Slatter, Mary; Zecca, Marco; Veys, Paul; Lankester, Arjan; Cant, Andrew; Skinner, Roderick; Wachowiak, Jacek; Glogova, Evgenia; Pötschger, Ulrike; Peters, Christina.

In: Pediatric Blood and Cancer, Vol. 63, No. 1, 01.01.2016, p. 139-148.

Research output: Contribution to journalArticle

Boztug, Heidrun ; Sykora, Karl Walter ; Slatter, Mary ; Zecca, Marco ; Veys, Paul ; Lankester, Arjan ; Cant, Andrew ; Skinner, Roderick ; Wachowiak, Jacek ; Glogova, Evgenia ; Pötschger, Ulrike ; Peters, Christina. / European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies. In: Pediatric Blood and Cancer. 2016 ; Vol. 63, No. 1. pp. 139-148.
@article{30eebb9aa2f04456aaba240926ad211c,
title = "European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies",
abstract = "Background: Standard myeloablative conditioning regimens for children with hematological malignancies undergoing allogeneic HSCT are based mainly on total body irradiation or busulfan. Their serious short-and long-term side effects warranted the exploration of less toxic alternatives. Treosulfan is increasingly used for adults and children before HSCT due to its potent immunosuppressive and cytotoxic effects combined with low organ toxicity. Procedure: To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010. Results: Early regimen-related toxicity was low and mainly gastrointestinal. Veno-occlusive disease and neurological toxicity were rare. There was no association of toxicity with type of disease or treosulfan dose. High-grade early toxicity was not higher in infants or patients undergoing second or later transplantation. Treatment related mortality was low at 14{\%}. Three-year event-free survival was 45±4{\%} and not significantly influenced by number of transplants, however it appeared to be significantly better for infants (P = 0.022). When compared to treosulfan plus fludarabine, the combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) resulted in significantly better overall survival (OS, P = 0.048) and a trend toward better EFS. Conclusions: Treosulfan based conditioning is a safe and effective approach for children with hematological malignancies, including and importantly for infants and those patients undergoing second or later transplantation.",
keywords = "Children, Hematological malignancy, Stem cell transplantation, Toxicity, Treosulfan",
author = "Heidrun Boztug and Sykora, {Karl Walter} and Mary Slatter and Marco Zecca and Paul Veys and Arjan Lankester and Andrew Cant and Roderick Skinner and Jacek Wachowiak and Evgenia Glogova and Ulrike P{\"o}tschger and Christina Peters",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/pbc.25764",
language = "English",
volume = "63",
pages = "139--148",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies

AU - Boztug, Heidrun

AU - Sykora, Karl Walter

AU - Slatter, Mary

AU - Zecca, Marco

AU - Veys, Paul

AU - Lankester, Arjan

AU - Cant, Andrew

AU - Skinner, Roderick

AU - Wachowiak, Jacek

AU - Glogova, Evgenia

AU - Pötschger, Ulrike

AU - Peters, Christina

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: Standard myeloablative conditioning regimens for children with hematological malignancies undergoing allogeneic HSCT are based mainly on total body irradiation or busulfan. Their serious short-and long-term side effects warranted the exploration of less toxic alternatives. Treosulfan is increasingly used for adults and children before HSCT due to its potent immunosuppressive and cytotoxic effects combined with low organ toxicity. Procedure: To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010. Results: Early regimen-related toxicity was low and mainly gastrointestinal. Veno-occlusive disease and neurological toxicity were rare. There was no association of toxicity with type of disease or treosulfan dose. High-grade early toxicity was not higher in infants or patients undergoing second or later transplantation. Treatment related mortality was low at 14%. Three-year event-free survival was 45±4% and not significantly influenced by number of transplants, however it appeared to be significantly better for infants (P = 0.022). When compared to treosulfan plus fludarabine, the combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) resulted in significantly better overall survival (OS, P = 0.048) and a trend toward better EFS. Conclusions: Treosulfan based conditioning is a safe and effective approach for children with hematological malignancies, including and importantly for infants and those patients undergoing second or later transplantation.

AB - Background: Standard myeloablative conditioning regimens for children with hematological malignancies undergoing allogeneic HSCT are based mainly on total body irradiation or busulfan. Their serious short-and long-term side effects warranted the exploration of less toxic alternatives. Treosulfan is increasingly used for adults and children before HSCT due to its potent immunosuppressive and cytotoxic effects combined with low organ toxicity. Procedure: To further investigate the role of treosulfan conditioning in children, the EBMT Pediatric diseases working party performed a retrospective analysis of 193 children with hematological malignancies (ALL n = 71, AML n = 47, MDS/MPS n = 40, other leukemia/lymphoma n = 25) undergoing allogeneic HSCT following treosulfan between January 2005 and July 2010. Results: Early regimen-related toxicity was low and mainly gastrointestinal. Veno-occlusive disease and neurological toxicity were rare. There was no association of toxicity with type of disease or treosulfan dose. High-grade early toxicity was not higher in infants or patients undergoing second or later transplantation. Treatment related mortality was low at 14%. Three-year event-free survival was 45±4% and not significantly influenced by number of transplants, however it appeared to be significantly better for infants (P = 0.022). When compared to treosulfan plus fludarabine, the combination of treosulfan, fludarabine and an alkylator (either thiotepa or melphalan) resulted in significantly better overall survival (OS, P = 0.048) and a trend toward better EFS. Conclusions: Treosulfan based conditioning is a safe and effective approach for children with hematological malignancies, including and importantly for infants and those patients undergoing second or later transplantation.

KW - Children

KW - Hematological malignancy

KW - Stem cell transplantation

KW - Toxicity

KW - Treosulfan

UR - http://www.scopus.com/inward/record.url?scp=84951568738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951568738&partnerID=8YFLogxK

U2 - 10.1002/pbc.25764

DO - 10.1002/pbc.25764

M3 - Article

C2 - 26398915

AN - SCOPUS:84951568738

VL - 63

SP - 139

EP - 148

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -